Researchers work inside a laboratory at BeiGene’s research and development centre in Beijing. Photo: Bloomberg
Why Chinese biotech companies are not for faint-hearted investors
- CK Life Sciences is up 97 per cent since announcing favourable clinical trial results for a skin cancer drug four weeks ago
- But some analysts prefer proven big players with approved drugs and large marketing teams
Topic |
Health in China
Researchers work inside a laboratory at BeiGene’s research and development centre in Beijing. Photo: Bloomberg